Cellular trafficking is essential to maintain critical biological functions. Mutations in 346 genes, most of them described in the last 5 years, are associated with disorders of cellular trafficking. Whereas initially restricted to membrane trafficking, the recent detection of many diseases has contributed to the discovery of new biological pathways. Accordingly, we propose to redesign this rapidly growing group of diseases combining biological mechanisms and clinical presentation into the following categories: (i) membrane trafficking (including organelle-related); (ii) membrane contact sites; (iii) autophagy; (iv) cytoskeleton-related. We present the most recently described pathophysiological findings, disorders and phenotypes. Although all tissues and organs are affected, the nervous system is especially vulnerable.
Autophagy , Organelles , Autophagy/genetics , Cytoskeleton/genetics
In view of the rapidly expanding number of IMD discovered by next generation sequencing, we propose a simplified classification of IMD that mixes elements from a clinical diagnostic perspective and a pathophysiological approach based on three large categories. We highlight the increasing importance of complex molecule metabolism and its connection with cell biology processes. Small molecule disorders have biomarkers and are divided in two subcategories: accumulation and deficiency. Accumulation of small molecules leads to acute or progressive postnatal "intoxication", present after a symptom-free interval, aggravated by catabolism and food intake. These treatable disorders must not be missed! Deficiency of small molecules is due to impaired synthesis of compounds distal to a block or altered transport of essential molecules. This subgroup shares many clinical characteristics with complex molecule disorders. Complex molecules (like glycogen, sphingolipids, phospholipids, glycosaminoglycans, glycolipids) are poorly diffusible. Accumulation of complex molecules leads to postnatal progressive storage like in glycogen and lysosomal storage disorders. Many are treatable. Deficiency of complex molecules is related to the synthesis and recycling of these molecules, which take place in organelles. They may interfere with fÅtal development. Most present as neurodevelopmental or neurodegenerative disorders unrelated to food intake. Peroxisomal disorders, CDG defects of intracellular trafficking and processing, recycling of synaptic vesicles, and tRNA synthetases also belong to this category. Only few have biomarkers and are treatable. Disorders involving primarily energy metabolism encompass defects of membrane carriers of energetic molecules as well as cytoplasmic and mitochondrial metabolic defects. This oversimplified classification is connected to the most recent available nosology of IMD.
Metabolism, Inborn Errors/classification , Metabolism, Inborn Errors/therapy , Humans , Infant, Newborn , Metabolic Networks and Pathways , Metabolism, Inborn Errors/diagnosis , Metabolism, Inborn Errors/genetics , Neonatal Screening , Research Design
It has become increasingly evident that inborn errors of metabolism (IEMs) are particularly prevalent as diseases of the nervous system and that a broader, more inclusive definition of IEM is necessary. In fact, as long as biochemistry is involved, any kind of monogenic disease can become an IEM. This new, extended definition includes new categories and mechanisms, and as a general trend will go beyond a single biochemical pathway and/or organelle, and will appear as a connection of multiple crossroads in a system biology approach.From one side, a simplified and updated classification of IEM is presented that mixes elements from the diagnostic approach with pathophysiological considerations into three large categories based on the size of molecules ("small and simple" or "large and complex") and their implication in energy metabolism. But from another side, whatever their size, metabolites involved in IEM may behave in the brain as signalling molecules, structural components and fuels, and many metabolites have more than one role. Neurometabolism is becoming more relevant, not only in relation to these new categories of diseases but also as a necessary way to explain the mechanisms of brain damage in classically defined categories of IEM. Brain metabolism, which has been largely disregarded in the traditional approach to investigating and treating neurological diseases, is a major clue and probably the next imminent "revolution" in neurology and neuroscience. Biochemistry (metabolism) and cell neurobiology need to meet. Additionally, the brain should be studied as a system (connecting different levels of complexity).
Brain/physiopathology , Metabolism, Inborn Errors/diagnosis , Nervous System Diseases/etiology , Signal Transduction , Energy Metabolism , Humans , Metabolism, Inborn Errors/classification , Metabolism, Inborn Errors/complications
Until recently, inborn errors of metabolism (IEM) were considered a pediatric specialty, as emphasized by the term "inborn," and the concept of adult onset IEM has only very recently reached the adult medical community. Still, an increasing number of adult onset IEM have now been recognized, as new metabolomics and molecular diagnostic techniques have become available. Here, we discuss possible mechanisms underlying phenotypic variability in adult versus children with IEM. Specifically, phenotypic severity and age of onset are expected to be modulated by differences in residual protein activity possibly driven by various genetic factors. Phenotypic variability may also occur in the context of similar protein expression, which suggests the intervention of environmental, ontogenic, and aging factors.
Metabolism, Inborn Errors/diagnosis , Adult , Age Factors , Child , Genetic Association Studies , Humans , Metabolism, Inborn Errors/genetics , Phenotype
In the last recent years, the -omics era has already transformed child neurology. Next generation sequencing (NGS) has identified many novel disease causing genes and phenotypes. While genetics is of great importance as a diagnostic tool, it is less helpful when it comes to a comprehensive understanding of mechanisms of brain dysfunction. Child neurologists are at high risk of being lost in genomics if they do not face the necessity of a new approach in their clinical practice. The large amount of data provided by NGS is just one more element in a complex puzzle. Different levels of complexity should be integrated in the much-needed novel child neurology paradigm. Classically, the descriptions of neurological diseases have relied on neuroanatomy and neurophysiology. However, metabolism, which strongly orchestrates the regulation of neuronal functions, has been mostly neglected in the study of brain disorders. Paradoxically, inborn errors of metabolism (IEM) have moved in the opposite direction. With more than 1100 IEM, almost 80% of which exhibit neurological symptoms, they have evolved from being initially considered as mere anecdotes to be a fundamental requisite in neuropediatric educational programs. Additionally, new complex molecule defects are leading to integrate classic metabolism and cell biology into the specific compartmentalized structure of the nervous system ("cellular neurometabolism"). This article is a brief summary of the updated IEM classification combined with major neurological presentations in a tentative towards a pathophysiology based clinical practice in child neurology. In particular we emphasize a clinical approach focused in a continuum/spectrum of symptoms
En los últimos años, la era -ómica ya ha transformado la neuropediatría. La secuenciación de alto rendimiento -next generation sequencing (NGS)- ha permitido identificar numerosos genes y fenotipos nuevos que provocan enfermedades. Aunque la genética tiene indudablemente una gran importancia como herramienta diagnóstica, no es de tanta utilidad cuando se trata de obtener una comprensión más amplia de los mecanismos involucrados en la disfunción cerebral. Los neuropediatras corren el riesgo de perderse en la genómica si no asumen la necesidad de un nuevo enfoque en su práctica clínica. La gran cantidad de datos que arroja la NGS es simplemente un elemento más en un complejo rompecabezas. Se deberían integrar distintos niveles de complejidad en el nuevo paradigma de la neuropediatría que tanto se echa en falta. Tradicionalmente, las descripciones de las enfermedades neurológicas se han basado en la neuroanatomía y la neurofisiología. Sin embargo, el metabolismo, que tiene un papel crucial en la regulación de las funciones neuronales, se ha obviado en la mayoría de estudios sobre los trastornos cerebrales. Paradójicamente, los errores congénitos del metabolismo (ECM) han tomado la dirección contraria. Con un total de más de 1.100 ECM, casi el 80% de los cuales manifiestan síntomas neurológicos, han pasado de considerarse inicialmente como anecdóticos a constituir un elemento fundamental en cualquier programa de educación neuropediátrica. Además, los nuevos defectos hallados en las moléculas complejas están promoviendo la integración del metabolismo y la biología celular clásicos en la estructura compartimentada específica del sistema nervioso ('neurometabolismo celular'). Este artículo constituye un breve resumen de la clasificación de los ECM actualizada en combinación con las principales presentaciones neurológicas en un intento de lograr una práctica clínica neuropediátrica basada en la fisiopatología. De manera particular, hacemos hincapié en un enfoque clínico centrado en un amplio continuo/espectro de síntomas
Humans , Child , Metabolism, Inborn Errors/complications , Nervous System Diseases/etiology , Motor Disorders/complications
The specialty of inherited metabolic disease is at the forefront of progress in medicine, with new methods in metabolomics and genomics identifying the molecular basis for a growing number of conditions and syndromes. This review presents an updated pathophysiologic classification of inborn errors of metabolism and a method of clinical screening in neonates, late-onset emergencies, neurologic deterioration, and other common clinical scenarios. When and how to investigate a metabolic disorder is presented to encourage physicians to use sophisticated biochemical investigations and not miss a treatable disorder.
Metabolism, Inborn Errors/diagnosis , Neonatal Screening/methods , Humans , Infant , Infant, Newborn , Metabolism, Inborn Errors/physiopathology , Metabolism, Inborn Errors/therapy
Inborn errors of metabolism (IEMs) are particularly frequent as diseases of the nervous system. In the pediatric neurologic presentations of IEMs neurodevelopment is constantly disturbed and in fact, as far as biochemistry is involved, any kind of monogenic disease can become an IEM. Clinical features are very diverse and may present as a neurodevelopmental disorder (antenatal or late-onset), as well as an intermittent, a fixed chronic, or a progressive and late-onset neurodegenerative disorder. This also occurs within the same disorder in which a continuum spectrum of severity is frequently observed. In general, the small molecule defects have screening metabolic markers and many are treatable. By contrast only a few complex molecules defects have metabolic markers and most of them are not treatable so far. Recent molecular techniques have considerably contributed in the description of many new diseases and unexpected phenotypes. This paper provides a comprehensive list of IEMs that affect neurodevelopment and may also present with neurodegeneration.
Las enfermedades hereditarias del metabolismo (EHM) afectan con gran frecuencia al sistema nervioso. En sus formas neuropediátricas el neurodesarrollo se encuentra siempre afectado. En realidad, cualquier enfermedad monogénica cuya fisiopatología implique una alteración bioquímica puede ser considerada como una EHM. Las presentaciones clínicas son muy diversas en forma de trastorno del desarrollo antenatal o tardío, o bien de una enfermedad neurodegenerativa a brotes intermitentes, de carácter crónico o progresivo de debut tardío. En una misma enfermedad pueden darse diferentes espectros de gravedad. En general, las EHM que afectan a las moléculas pequeñas tienen marcadores metabólicos diagnósticos y muchas de ellas son tratables. Por contra, las EHM de las moléculas complejas tienen raramente marcadores metabólicos conocidos y la mayoría no tienen un tratamiento a día de hoy. Las técnicas de secuenciación masiva han permitido la descripción de numerosas nuevas enfermedades y fenotipos inesperados. Este artículo ofrece una lista completa de EHM que afectan el neurodesarrollo y pueden presentarse también como enfermedades neurodegenerativas.
Les maladies héréditaires du métabolisme (MHM) affectent très fréquemment le système nerveux. Dans leurs formes neuropédiatriques, le neurodéveloppement est toujours perturbé et dès l'instant qu'elle implique un mécanisme biochimique, toute maladie monogénique peut devenir une MHM. Les présentations cliniques sont très diverses et peuvent s'exprimer sous la forme d'un trouble du neurodéveloppement (anténatal ou à début tardif) ou d'une maladie neurodégénérative intermittente, chronique stable ou progressive à début tardif. Ceci peut aussi s'observer au sein d'une même maladie, ou un continuum de sévérité est fréquemment constaté. En général, les MHM affectant les petites molécules biochimiques ont des marqueurs métaboliques de dépistage et beaucoup sont traitables. Au contraire, les MHM affectant les molécules biochimiques complexes ont rarement des marqueurs métaboliques et la plupart d'entre elles ne sont pas traitables jusqu'à présent. Les techniques moléculaires récentes ont permis la description de nombreuses nouvelles maladies et de phénotypes inattendus. Cet article donne une liste complète des MHM affectant le neurodéveloppement et pouvant aussi se présenter comme des maladies neurodégénératives.
Brain/growth & development , Metabolism, Inborn Errors/diagnosis , Neurodegenerative Diseases/diagnosis , Neurodevelopmental Disorders/diagnosis , Animals , Disease Models, Animal , Humans , Metabolism, Inborn Errors/physiopathology , Neurodegenerative Diseases/physiopathology , Neurodevelopmental Disorders/physiopathology , Neurons/pathology
Hereditary spastic paraplegias are heterogeneous neurological disorders characterized by a pyramidal syndrome with symptoms predominantly affecting the lower limbs. Some limited pyramidal involvement also occurs in patients with an autosomal recessive neurocutaneous syndrome due to ALDH18A1 mutations. ALDH18A1 encodes delta-1-pyrroline-5-carboxylate synthase (P5CS), an enzyme that catalyses the first and common step of proline and ornithine biosynthesis from glutamate. Through exome sequencing and candidate gene screening, we report two families with autosomal recessive transmission of ALDH18A1 mutations, and predominant complex hereditary spastic paraplegia with marked cognitive impairment, without any cutaneous abnormality. More interestingly, we also identified monoallelic ALDH18A1 mutations segregating in three independent families with autosomal dominant pure or complex hereditary spastic paraplegia, as well as in two sporadic patients. Low levels of plasma ornithine, citrulline, arginine and proline in four individuals from two families suggested P5CS deficiency. Glutamine loading tests in two fibroblast cultures from two related affected subjects confirmed a metabolic block at the level of P5CS in vivo. Besides expanding the clinical spectrum of ALDH18A1-related pathology, we describe mutations segregating in an autosomal dominant pattern. The latter are associated with a potential trait biomarker; we therefore suggest including amino acid chromatography in the clinico-genetic work-up of hereditary spastic paraplegia, particularly in dominant cases, as the associated phenotype is not distinct from other causative genes.
Aldehyde Dehydrogenase/genetics , Mutation/genetics , Ornithine/genetics , Ornithine/metabolism , Spastic Paraplegia, Hereditary/genetics , Adolescent , Adult , Arginine/metabolism , Female , Glutamic Acid/metabolism , Humans , Male , Middle Aged , Pedigree , Phenotype , Spastic Paraplegia, Hereditary/metabolism , Young Adult
In a review published in 2012, we delineated 14 inborn errors of metabolism (IEM) related to defects in biosynthesis of complex lipids, particularly phospholipids and sphingolipids (Lamari et al 2013). Given the numerous roles played by these molecules in membrane integrity, cell structure and function, this group of diseases is rapidly expanding as predicted. Almost 40 new diseases related to genetic defects in enzymes involved in the biosynthesis and remodelling of phospholipids, sphingolipids and complex fatty acids are now reported. While the clinical phenotype associated with these defects is currently difficult to outline, with only a few patients identified to date, it appears that all organs and systems may be affected - central and peripheral nervous system, eye, muscle, skin, bone, liver, immune system, etc. This chapter presents an introductive overview of this new group of IEM. More broadly, this special issue provides an update on other IEM involving complex lipids, namely dolichol and isoprenoids, glycolipids and congenital disorders of glycosylation, very long chain fatty acids and plasmalogens. Likewise, more than 100 IEM may actually lead to primary or secondary defects of complex lipids synthesis and remodelling. Because of the implication of several cellular compartments, this new group of disorders affecting the synthesis and remodelling of complex molecules challenges our current classification of IEM still largely based on cellular organelles--i.e. mitochondrial, lysosomal, peroxisomal disorders. While most of these new disorders have been identified by next generation sequencing, we wish to emphasize the promising role of lipidomics in deciphering their pathophysiology and identifying therapeutic targets.
Lipid Metabolism , Lipids/chemistry , Metabolism, Inborn Errors/genetics , Energy Metabolism , Epidermis/metabolism , Fatty Acids/biosynthesis , Fatty Acids/chemistry , Homeostasis , Humans , Lipids/biosynthesis , Phenotype , Phospholipids/biosynthesis , Phospholipids/chemistry , Signal Transduction , Sphingolipids/biosynthesis , Sphingolipids/chemistry , Water/chemistry
Over one hundred diseases related to inherited defects of complex lipids synthesis and remodeling are now reported. Most of them were described within the last 5 years. New descriptions and phenotypes are expanding rapidly. While the associated clinical phenotype is currently difficult to outline, with only a few patients identified, it appears that all organs and systems may be affected. The main clinical presentations can be divided into (1) Diseases affecting the central and peripheral nervous system. Complex lipid synthesis disorders produce prominent motor manifestations due to upper and/or lower motoneuron degeneration. Motor signs are often complex, associated with other neurological and extra-neurological signs. Three neurological phenotypes, spastic paraparesis, neurodegeneration with brain iron accumulation and peripheral neuropathies, deserve special attention. Many apparently well clinically defined syndromes are not distinct entities, but rather clusters on a continuous spectrum, like for the PNPLA6-associated diseases, extending from Boucher-Neuhauser syndrome via Gordon Holmes syndrome to spastic ataxia and pure hereditary spastic paraplegia; (2) Muscular/cardiac presentations; (3) Skin symptoms mostly represented by syndromic (neurocutaneous) and non syndromic ichthyosis; (4) Retinal dystrophies with syndromic and non syndromic retinitis pigmentosa, Leber congenital amaurosis, cone rod dystrophy, Stargardt disease; (5) Congenital bone dysplasia and segmental overgrowth disorders with congenital lipomatosis; (6) Liver presentations characterized mainly by transient neonatal cholestatic jaundice and non alcoholic liver steatosis with hypertriglyceridemia; and (7) Renal and immune presentations. Lipidomics and molecular functional studies could help to elucidate the mechanism(s) of dominant versus recessive inheritance observed for the same gene in a growing number of these disorders.
Lipid Metabolism, Inborn Errors/diagnosis , Lipids/chemistry , Ataxia/diagnosis , Bone Diseases, Developmental/diagnosis , Fatty Liver/diagnosis , Humans , Hypertriglyceridemia/diagnosis , Ichthyosis/diagnosis , Jaundice/diagnosis , Leber Congenital Amaurosis/diagnosis , Lipid Metabolism, Inborn Errors/genetics , Lipomatosis/diagnosis , Liver Diseases/diagnosis , Macular Degeneration/diagnosis , Neurodegenerative Diseases/diagnosis , Paraparesis, Spastic/diagnosis , Peripheral Nervous System Diseases/diagnosis , Phenotype , Retinal Dystrophies/diagnosis , Retinitis Pigmentosa/diagnosis , Spastic Paraplegia, Hereditary/diagnosis , Stargardt Disease
In non-diabetic adult patients, hypoglycaemia may be related to drugs, critical illness, cortisol or glucagon insufficiency, non-islet cell tumour, insulinoma, or it may be surreptitious. Nevertheless, some hypoglycaemic episodes remain unexplained, and inborn errors of metabolism (IEM) should be considered, particularly in cases of multisystemic involvement. In children, IEM are considered a differential diagnosis in cases of hypoglycaemia. In adulthood, IEM-related hypoglycaemia can persist in a previously diagnosed childhood disease. Hypoglycaemia may sometimes be a presenting sign of the IEM. Short stature, hepatomegaly, hypogonadism, dysmorphia or muscular symptoms are signs suggestive of IEM-related hypoglycaemia. In both adults and children, hypoglycaemia can be clinically classified according to its timing. Postprandial hypoglycaemia can be an indicator of either endogenous hyperinsulinism linked to non-insulinoma pancreatogenic hypoglycaemia syndrome (NIPHS, unknown incidence in adults) or very rarely, inherited fructose intolerance. Glucokinase-activating mutations (one family) are the only genetic disorder responsible for NIPH in adults that has been clearly identified so far. Exercise-induced hyperinsulinism is linked to an activating mutation of the monocarboxylate transporter 1 (one family). Fasting hypoglycaemia may be caused by IEM that were already diagnosed in childhood and persist into adulthood: glycogen storage disease (GSD) type I, III, 0, VI and IX; glucose transporter 2 deficiency; fatty acid oxidation; ketogenesis disorders; and gluconeogenesis disorders. Fasting hypoglycaemia in adulthood can also be a rare presenting sign of an IEM, especially in GSD type III, fatty acid oxidation [medium-chain acyl-CoA dehydrogenase (MCAD), ketogenesis disorders (3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) lyase deficiency, and gluconeogenesis disorders (fructose-1,6-biphosphatase deficiency)].
Hypoglycemia/diagnosis , Hypoglycemia/etiology , Metabolism, Inborn Errors/complications , Metabolism, Inborn Errors/diagnosis , Adult , Humans , Metabolism, Inborn Errors/genetics , Metabolism, Inborn Errors/physiopathology , Rare Diseases
Most inborn errors of metabolism (IEM) are recessive, genetically transmitted diseases and are classified into 3 main groups according to their mechanisms: cellular intoxication, energy deficiency, and defects of complex molecules. They can be associated with endocrine manifestations, which may be complications from a previously diagnosed IEM of childhood onset. More rarely, endocrinopathies can signal an IEM in adulthood, which should be suspected when an endocrine disorder is associated with multisystemic involvement (neurological, muscular, hepatic features, etc.). IEM can affect all glands, but diabetes mellitus, thyroid dysfunction and hypogonadism are the most frequent disorders. A single IEM can present with multiple endocrine dysfunctions, especially those involving energy deficiency (respiratory chain defects), and metal (hemochromatosis) and storage disorders (cystinosis). Non-autoimmune diabetes mellitus, thyroid dysfunction and/or goiter and sometimes hypoparathyroidism should steer the diagnosis towards a respiratory chain defect. Hypogonadotropic hypogonadism is frequent in haemochromatosis (often associated with diabetes), whereas primary hypogonadism is reported in Alström disease and cystinosis (both associated with diabetes, the latter also with thyroid dysfunction) and galactosemia. Hypogonadism is also frequent in X-linked adrenoleukodystrophy (with adrenal failure), congenital disorders of glycosylation, and Fabry and glycogen storage diseases (along with thyroid dysfunction in the first 3 and diabetes in the last). This is a new and growing field and is not yet very well recognized in adulthood despite its consequences on growth, bone metabolism and fertility. For this reason, physicians managing adult patients should be aware of these diagnoses.
Endocrine Glands/physiopathology , Metabolism, Inborn Errors/complications , Adult , Humans , Metabolism, Inborn Errors/genetics , Metabolism, Inborn Errors/physiopathology
OBJECTIVE: To describe the long-term metabolic outcome of children with congenital hyperinsulinism after near-total or partial elective pancreatectomy. RESEARCH DESIGN AND METHODS: Patients (n = 105: 58 diffuse and 47 focal congenital hyperinsulinism) received operations between 1984 and 2006. Follow-up consisted of periodic measurements of pre- and postprandial plasma glucose over 24 h, OGTT, and IVGTT. Cumulative incidence of hypo- or hyperglycemia/insulin treatment was estimated by Kaplan-Meier analysis. RESULTS: After near-total pancreatectomy, 59% of children with diffuse congenital hyperinsulinism still presented mild or asymptomatic hypoglycemia that responded to medical treatments and disappeared within 5 years. One-third of the patients had both preprandial hypoglycemia and postprandial hyperglycemia. Hyperglycemia was found in 53% of the patients immediately after surgery; its incidence increased regularly to 100% at 13 years. The cumulative incidence of insulin-treated patients was 42% at 8 years and reached 91% at 14 years, but the progression to insulin dependence was very variable among the patients. Plasma insulin responses to IVGTT and OGTT correlated well with glycemic alterations. In focal congenital hyperinsulinism, hypoglycemia or hyperglycemia were rare, mild, and transient. CONCLUSIONS: Patients with focal congenital hyperinsulinism are cured of hypoglycemia after limited surgery, while the outcome of diffuse congenital hyperinsulinism is very variable after near-total pancreatectomy. The incidence of insulin-dependent diabetes is very high in early adolescence.
Blood Glucose/metabolism , Congenital Hyperinsulinism/blood , Congenital Hyperinsulinism/surgery , Pancreatectomy , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Insulin/blood , Kaplan-Meier Estimate , Male , Treatment Outcome
Hyperargininemia is a rare inborn error of metabolism due to arginase deficiency, which is inherited in an autossomal recessive manner. Arginase is the final enzyme of the urea cycle and catalyzes the conversion of arginine to urea and ornithine. This condition typically presents in early childhood (between 2 and 4 years of age) with developmental delay associated with progressive spastic paraparesis. Neonatal presentation is very uncommon with a poorly described outcome. Here, we discuss two cases of neonatal cholestasis as initial clinical presentation of hyperargininemia. In case 1, diagnosis was established at 2 months of age upon investigation of the etiology of cholestatic injury pattern and hepatosplenomegaly, and treatment was then initiated at when the patient was 3 months old. Unfortunately, the patient had progressive biliary cirrhosis to end-stage liver disease complicated with portal hypertension for which she underwent successful orthotopic liver transplant at 7 years of age. In case 2, hyperargininemia was identified through newborn screening and treatment was started when patient was 21 days old. Cholestasis was only identified in the patient's further evaluation and it resolved 2 weeks into treatment. The patient is currently 18 months old and her development and neurological examination remain unremarkable. Neonatal cholestasis as first presentation of hyperargininemia is rare, but this disorder should be included in the differential diagnosis of unexplained cholestasis in the neonate. In fact, these two cases suggest that arginase deficiency may be the cause of cholestatic liver disease.
Cholestasis/etiology , Hyperargininemia/complications , Amino Acids, Essential/therapeutic use , Arginase/genetics , Arginase/metabolism , Arginine/blood , Biomarkers/blood , Child , Child Development , Child, Preschool , Cholestasis/diagnosis , Cholestasis/therapy , Diet, Protein-Restricted , Disease Progression , End Stage Liver Disease/etiology , Female , Genetic Predisposition to Disease , Humans , Hyperargininemia/diagnosis , Hyperargininemia/enzymology , Hyperargininemia/genetics , Hyperargininemia/therapy , Hypertension, Portal/etiology , Infant , Infant, Newborn , Liver Cirrhosis, Biliary/etiology , Liver Transplantation , Neonatal Screening , Phenotype , Treatment Outcome
AIM: To describe the phenotype and genotype of pyruvate dehydrogenase complex (PDHc) deficiency. METHOD: Twenty-two participants with enzymologically and genetically confirmed PDHc deficiency were analysed for clinical and imaging features over a 15-year period. RESULTS: Four groups were identified: (1) those with neonatal encephalopathy with lactic acidosis (one male, four females; diagnosis at birth); (2) those with non-progressive infantile encephalopathy (three males, three females; age at diagnosis 2-9mo); (3) those with Leigh syndrome (eight males; age at diagnosis 1-13mo); and (4) those with relapsing ataxia (three males; 18-30mo). Seventeen mutations involved PDHA1 (a hotspot was identified in exons 6, 7, and 8 in seven males with Leigh syndrome or recurrent ataxia). Mutations in the PDHX gene (five cases) were correlated with non-progressive encephalopathy and long-term survival in four cases. INTERPRETATION: Two types of neurological involvement were identified. Abnormal prenatal brain development resulted in severe non-progressive encephalopathy with callosal agenesis, gyration anomalies, microcephaly with intrauterine growth retardation, or dysmorphia in both males and females (12 cases). Acute energy failure in infant life produced basal ganglia lesions with paroxysmal dystonia, neuropathic ataxia due to axonal transport dysfunction, or epilepsy only in males (11 cases). The ketogenic diet improved only paroxysmal dysfunction, providing an additional argument in favour of paroxysmal energy failure.
Mutation/genetics , Nervous System Diseases/genetics , Nervous System Diseases/pathology , Phenotype , Pyruvate Dehydrogenase Complex Deficiency Disease/genetics , Pyruvate Dehydrogenase Complex Deficiency Disease/pathology , Pyruvate Dehydrogenase Complex/genetics , Adolescent , Brain/pathology , Female , Genetic Predisposition to Disease/genetics , Humans , Longitudinal Studies , Magnetic Resonance Imaging/methods , Male , Motor Skills Disorders/etiology , Nervous System Diseases/drug therapy , Nervous System Diseases/etiology , Peripheral Nervous System/pathology , Pyruvate Dehydrogenase Complex Deficiency Disease/drug therapy , Retrospective Studies , Thiamine/therapeutic use , Vitamin B Complex/therapeutic use
Brain Diseases, Metabolic, Inborn/diagnosis , Brain Diseases, Metabolic, Inborn/complications , Brain Diseases, Metabolic, Inborn/etiology , Epilepsy/etiology , Epilepsy/metabolism , Humans , Infant, Newborn , Intellectual Disability/etiology , Intellectual Disability/metabolism , Movement Disorders/etiology
Although they are classically viewed as paediatric diseases, it is now recognized that inborn errors of metabolism (IEMs) can present at any age from childhood to adulthood. IEMs can involve the peripheral nervous system, mostly as part of a more diffuse neurological or systemic clinical picture. However, in some cases, the neuropathy can be the unique initial sign. Here, based on our personal experience and on a comprehensive literature analysis, we review IEMs causing neuropathies in adults. Diseases were classified according to the predominant type of neuropathies into (1) acute neuropathies, (2) mononeuropathy multiplex, (3) chronic axonal polyneuropathies, (4) chronic demyelinating polyneuropathies, (5) small-fibre neuropathies, and (6) lower motor neuron disease.
Metabolism, Inborn Errors/diagnosis , Peripheral Nervous System Diseases/etiology , Acute Disease , Adolescent , Adult , Age of Onset , Chronic Disease , Decision Trees , Demyelinating Diseases/etiology , Diagnosis, Differential , Diagnostic Errors/prevention & control , Humans , Metabolism, Inborn Errors/classification , Metabolism, Inborn Errors/complications , Metabolism, Inborn Errors/epidemiology , Middle Aged , Mononeuropathies/etiology , Motor Neuron Disease/etiology , Polyneuropathies/etiology , Terminology as Topic
